Mavefund EN
Canopy Growth Corp logo

Canopy Growth Corp

CGC
Letzter Kurs (USD) US$1
Marktkapitalisierung (USD) US$449400.0
Kursänderung 12 Monate -44.47%
Loading the 12-month Mave Thesis and 1-month news signal

Start Heute Aktien Watchlist

Canopy Growth Corp Überblick

Branche: Drug Manufacturers Specialty & Generic

Sektor: Healthcare

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada. Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Cons

Research-Überblick

Letztes Berichtsdatum 2026-08-07

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Canopy Growth Corp (CGC): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
CGC · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Drug Manufacturers Specialty & Generic
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-07
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Canopy Growth Corp für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 07, 2026

Quarterly result summary

Revenue was $81.2 (reported). Net loss was -$0M. Adjusted EBITDA was $3.2.

Revenue $81.2 reported
Net loss -$0M reported
Adjusted EBITDA $3.2 reported

Was sich verändert hat

  • Revenue reported to $81.2.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 3.00/5
Canopy Growth Corp boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Eigenkapitalrendite

Score 1.69/5
Canopy Growth Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Canopy Growt... CGC US$449400
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 1.08/5
Canopy Growth Corp olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Canopy Growt... CGC US$449400
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Verschuldung

Score 2.32/5
Canopy Growth Corp registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
Canopy Growt... CGC US$449400
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Canopy Growth Corp logo

Canopy Growth Corp

US$1

US$449400.0

-6.14%

-44.47%